Key result
Verapamil inhibits PDGF-stimulated coronary smooth muscle cell proliferation but fails to suppress stretch-induced growth.
Answers are grounded in this paper and cite their sources.
Demonstrates that verapamil inhibits PDGF-induced but not pulsatile stretch-induced proliferation in human coronary smooth muscle cells, indicating limits to its antiatherogenic efficacy.
BACKGROUND: Vascular smooth muscle cell proliferation is the key event of coronary artery disease. Mechanical forces, in particular, pulsatile stretch and platelet-derived growth factor, may play an important role. METHODS AND RESULTS: Vascular smooth muscle cells were cultured from the media of human left descending coronary arteries obtained from organ donors using the explant method. To study effects of pulsatile stretch on vascular smooth muscle cell proliferation, a computer-controlled in vitro pulsatile stretch device was used. Cells were seeded onto Flex I culture plates with deformable membranes and exposed to pulsatile stretch (60 cycles per minute) and/or growth factors. Proliferation of smooth muscle cells was determined by 3H-thymidine incorporation. Pulsatile stretch markedly stimulated 3H-thymidine incorporation of coronary smooth muscle cells (180 +/- 15 to 432 +/- 27 cpm/10(5) cells; P < .05) after 24 hours and increased cell number after 6 days (10.3 +/- 0.7 x 10(4)/mL; P < .05). Platelet-derived growth factor-AB (0.01 to 10 ng/mL) concentration-dependently stimulated 3H-thymidine incorporation in coronary smooth muscle cells (EC50, 0.1 ng/mL) and had additive effects with pulsatile stretch. The Ca2+ antagonist verapamil (10(-7) to 10(-5) M) concentration-dependently inhibited proliferation stimulated by platelet-derived growth factor back to control levels (P < .05 to .01) but not that induced by pulsatile stretch. CONCLUSIONS: Pulsatile stretch and platelet-derived growth factor are potent stimuli for proliferation of coronary smooth muscle cells. The selective inhibitory effect of a Ca2+ antagonist on smooth muscle cell proliferation stimulated by platelet-derived growth factor but not by pulsatile stretch may explain why the drugs have only modest antiatherogenic effects in patients with coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Yang et al. (1993) studied Coronary artery disease / Vascular smooth muscle cell proliferation. Verapamil (with pulsatile stretch and platelet-derived growth factor-AB) vs. Control (untreated or unstretched cells) was evaluated on Proliferation of coronary smooth muscle cells determined by 3H-thymidine incorporation and cell number (p=<0.05). Verapamil (10^-7 to 10^-5 M) inhibited PDGF-stimulated coronary smooth muscle cell proliferation to control levels (P<.05 to .01), but not proliferation induced by pulsatile stretch.
Synapse has enriched 10 related papers. Consider them for comparative context: